BioNTech’s Bold Gamble: From Covid-19 Giants to Cancer Therapy Pioneers
BioNTech shifts focus from Covid-19 vaccines to mRNA-based cancer therapies, representing ambition and risk. 2024 earnings dropped to €1.08 per share from €1.90, with revenue down to €1.19 billion but…